RecruitingPhase 3NCT03925714
Impact of P53 and SIRT1 in Type 2 Diabetes
Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin
Sponsor
Sherief Abd-Elsalam
Enrollment
90 participants
Start Date
Apr 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
Investigating the impact of p53 and SIRT1 in the development of type 2 DM
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Prediabetic subjects.
Exclusion Criteria2
- Confirmed diabetes.
- Hepatic or renal impairment.
Interventions
OTHERlife style
life sryle control only
DRUGMetformin
metformin twice daily
DRUGNigetella salivata
NS twice daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03925714